Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) and Lucid Genomics announced on April 21, 2026 a compatibility collaboration under PacBio's Compatible partner program. The partnership certifies Lucid Genomics' tertiary analysis platform for PacBio HiFi long-read sequencing, enabling validated workflows from alignment and variant calling to clinical interpretation and methylation analysis.
The integration aims to streamline analysis, reduce integration risk, and accelerate time-to-insight for clinical and research labs using PacBio systems.
PacBio (NASDAQ: PACB) will report first quarter 2026 financial results and host a conference call on Thursday, May 7, 2026 at 4:30 p.m. ET (1:30 p.m. PT). The call will be webcast and available on the company's investor website.
Live listen and replay access are provided via the investor site at https://investor.pacificbiosciences.com/, toll-free dial-in 1-888-349-0136, and international dial-in 1-412-317-0459.
PacBio (NASDAQ: PACB) and Covaris announced a joint extraction-to-library workflow enabling HiFi long-read sequencing from FFPE tumor samples, integrating Covaris truXTRAC FFPE extraction with PacBio Kinnex library prep and Revio sequencing.
In studies across brain, kidney and uterine tumors the workflow produced >100 million HiFi reads per sample, mean read lengths of 750–1,500 bp, >11,000 structural variants and ~5 million small variants per sample, with ~60% of variants phased into haplotypes.
PacBio (NASDAQ: PACB) announced that Basecamp Research selected PacBio HiFi sequencing on the Revio system with SPRQ-Nx chemistry to power the Trillion Gene Atlas.
The collaboration will generate approximately 100,000 deeply sequenced samples from over 31 countries across 5 continents, creating the largest high-fidelity metagenomic dataset assembled to date.
PacBio (NASDAQ: PACB) appointed Christopher Gibson, Ph.D., to its Board of Directors on March 5, 2026. Dr. Gibson co-founded and chairs Recursion (NASDAQ: RXRX) and brings experience building AI-driven, high-dimensional biology platforms that integrate automation, sequencing-scale data, and machine learning to accelerate discovery.
This appointment aims to strengthen PacBio’s ability to develop data tools and advanced analytics for HiFi long-read sequencing datasets.
PacBio (NASDAQ: PACB) and DNAstack launched the HiFi Solves Global Consortium to create the first global federated dataset of HiFi whole genome sequencing for rare disease research. The consortium spans nearly 30 institutions across 15 countries and has connected or committed to connect >b>10,000 HiFi whole genomes, enabling cross-border queries while data remain under local control.
The platform, hosted by DNAstack at hifisolves.org, supports secure federated queries, preserves data sovereignty, and leverages HiFi accuracy to improve detection of challenging variants and accelerate diagnoses for rare disease patients.
PacBio (NASDAQ: PACB) management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 2, 2026 at 2:30 PM ET in Boston.
A live webcast will be available on the company's investor site and a replay will be accessible for at least 30 days, according to PacBio.
PacBio (NASDAQ: PACB) reported Q4 and full‑year 2025 results for the period ended December 31, 2025. Q4 revenue was $44.6M (up 14% YoY) and FY revenue was $160.0M. Non‑GAAP gross margin improved to 40% in Q4 and FY 2025. The company completed the sale of short‑read assets for $48.1M net cash and ended the year with $279.5M in cash, cash equivalents, and investments.
Notable operational items included record consumables revenue, strong Vega system placements, reduced non‑GAAP operating expenses, and a GAAP net loss of $546.4M for FY 2025.
PacBio (NASDAQ: PACB) is joining the iHope global rare-disease genomics network as its first long-read sequencing partner to integrate HiFi long-read whole-genome sequencing.
iHope supports more than 1,000 patients annually across 25 clinical sites in 14 countries. Integration is expected to begin in early 2026 and aims to improve detection of challenging variants and support future precision-therapeutic research.
PacBio (NASDAQ: PACB) completed the sale of select short-read sequencing intellectual property and related assets to Illumina, closing January 30, 2026. PacBio received $48.1 million in net cash proceeds, Illumina assumed certain liabilities, and granted PacBio a non-exclusive license back to specified intellectual property.
PacBio said the transaction sharpens its focus on long-read sequencing, accelerates SPRQ-Nx chemistry development, and strengthens the company balance sheet.